Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies

Gene-modification therapies are at the forefront of HIV-1 cure strategies. Chimeric antigen receptor (CAR)-T cells pose a potential approach to target infected cells during antiretroviral therapy or following analytical treatment interruption (ATI). However, there are technical challenges in the qua...

詳細記述

書誌詳細
出版年:Viruses
主要な著者: Amanda M. Buck, Tyler-Marie Deveau, Timothy J. Henrich, Amelia N. Deitchman
フォーマット: 論文
言語:英語
出版事項: MDPI AG 2023-05-01
主題:
オンライン・アクセス:https://www.mdpi.com/1999-4915/15/5/1126
_version_ 1849901832442216448
author Amanda M. Buck
Tyler-Marie Deveau
Timothy J. Henrich
Amelia N. Deitchman
author_facet Amanda M. Buck
Tyler-Marie Deveau
Timothy J. Henrich
Amelia N. Deitchman
author_sort Amanda M. Buck
collection DOAJ
container_title Viruses
description Gene-modification therapies are at the forefront of HIV-1 cure strategies. Chimeric antigen receptor (CAR)-T cells pose a potential approach to target infected cells during antiretroviral therapy or following analytical treatment interruption (ATI). However, there are technical challenges in the quantification of HIV-1-infected and CAR-T cells in the setting of lentiviral CAR gene delivery and also in the identification of cells expressing target antigens. First, there is a lack of validated techniques to identify and characterize cells expressing the hypervariable HIV gp120 in both ART-suppressed and viremic individuals. Second, close sequence homology between lentiviral-based CAR-T gene modification vectors and conserved regions of HIV-1 creates quantification challenges of HIV-1 and lentiviral vector levels. Consideration needs to be taken into standardizing HIV-1 DNA/RNA assays in the setting of CAR-T cell and other lentiviral vector-based therapies to avoid these confounding interactions. Lastly, with the introduction of HIV-1 resistance genes in CAR-T cells, there is a need for assays with single-cell resolution to determine the competence of the gene inserts to prevent CAR-T cells from becoming infected in vivo. As novel therapies continue to arise in the HIV-1 cure field, resolving these challenges in CAR-T-cell therapy will be crucial.
format Article
id doaj-art-e8ae42e5b7524f0b96429a0ae14449b4
institution Directory of Open Access Journals
issn 1999-4915
language English
publishDate 2023-05-01
publisher MDPI AG
record_format Article
spelling doaj-art-e8ae42e5b7524f0b96429a0ae14449b42025-08-20T00:59:04ZengMDPI AGViruses1999-49152023-05-01155112610.3390/v15051126Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure StrategiesAmanda M. Buck0Tyler-Marie Deveau1Timothy J. Henrich2Amelia N. Deitchman3Division of Experimental Medicine, University of California San Francisco, San Francisco, CA 94110, USADivision of Experimental Medicine, University of California San Francisco, San Francisco, CA 94110, USADivision of Experimental Medicine, University of California San Francisco, San Francisco, CA 94110, USADepartment of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94110, USAGene-modification therapies are at the forefront of HIV-1 cure strategies. Chimeric antigen receptor (CAR)-T cells pose a potential approach to target infected cells during antiretroviral therapy or following analytical treatment interruption (ATI). However, there are technical challenges in the quantification of HIV-1-infected and CAR-T cells in the setting of lentiviral CAR gene delivery and also in the identification of cells expressing target antigens. First, there is a lack of validated techniques to identify and characterize cells expressing the hypervariable HIV gp120 in both ART-suppressed and viremic individuals. Second, close sequence homology between lentiviral-based CAR-T gene modification vectors and conserved regions of HIV-1 creates quantification challenges of HIV-1 and lentiviral vector levels. Consideration needs to be taken into standardizing HIV-1 DNA/RNA assays in the setting of CAR-T cell and other lentiviral vector-based therapies to avoid these confounding interactions. Lastly, with the introduction of HIV-1 resistance genes in CAR-T cells, there is a need for assays with single-cell resolution to determine the competence of the gene inserts to prevent CAR-T cells from becoming infected in vivo. As novel therapies continue to arise in the HIV-1 cure field, resolving these challenges in CAR-T-cell therapy will be crucial.https://www.mdpi.com/1999-4915/15/5/1126CAR-T cellsHIV-1 cureHIV-1 envelope expressionlentiviral vectorsgene modificationeradication
spellingShingle Amanda M. Buck
Tyler-Marie Deveau
Timothy J. Henrich
Amelia N. Deitchman
Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
CAR-T cells
HIV-1 cure
HIV-1 envelope expression
lentiviral vectors
gene modification
eradication
title Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
title_full Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
title_fullStr Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
title_full_unstemmed Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
title_short Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies
title_sort challenges in hiv 1 latent reservoir and target cell quantification in car t cell and other lentiviral gene modifying hiv cure strategies
topic CAR-T cells
HIV-1 cure
HIV-1 envelope expression
lentiviral vectors
gene modification
eradication
url https://www.mdpi.com/1999-4915/15/5/1126
work_keys_str_mv AT amandambuck challengesinhiv1latentreservoirandtargetcellquantificationincartcellandotherlentiviralgenemodifyinghivcurestrategies
AT tylermariedeveau challengesinhiv1latentreservoirandtargetcellquantificationincartcellandotherlentiviralgenemodifyinghivcurestrategies
AT timothyjhenrich challengesinhiv1latentreservoirandtargetcellquantificationincartcellandotherlentiviralgenemodifyinghivcurestrategies
AT ameliandeitchman challengesinhiv1latentreservoirandtargetcellquantificationincartcellandotherlentiviralgenemodifyinghivcurestrategies